# US 2003/0223969 A1 · Method of modulating inflammatory response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0223969 A1
- Document ID: US20030223969A1
- Status: Published application
- Kind: A1
- Application number: 10/372,303
- Filed: 2003-02-25
- Published: 2003-12-04
- Earliest claimed: 2002-03-15
- Assignees: University of Michigan
- Inventors: H. David Humes
- Web page: https://patentgrep.com/patent/US20030223969A1

## CPC

- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- A61M 1/3472: {with treatment of the filtrate}
- A61M 1/3475: {with filtrate treatment agent in the same enclosure as the membrane}
- A61M 1/3489: {by biological cells, e.g. bioreactor}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/18: of the parathyroid hormones
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61M 1/3623: {Means for actively controlling temperature of blood}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.

## Claims

### Claim 1

A method of modulating the levels of at least one inflammatory cytokine in a patient in need thereof, comprising:
contacting, outside of the kidney, at least a portion of the body fluid of the patient with renal tubule cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting of end-stage renal disease, chronic renal insufficiency, acute renal failure, sepsis, malnutrition, chronic congestive heart failure, inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, dermatomyositis, diabetes mellitus Type I, thyroiditis, psoriasis, Guillian Barre syndrome, multiple sclerosis, and atherosclerosis, or other autoimmune disorders.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting of end-stage renal disease, chronic renal insufficiency, acute renal failure, and sepsis.

### Claim 4 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting malnutrition, chronic congestive heart failure, inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, dermatomyositis, diabetes mellitus Type I, thyroiditis, psoriasis, Guillian Barre syndrome, multiple sclerosis, and atherosclerosis, or other autoimmune disorders.

### Claim 5 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

### Claim 6 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from rheumatoid arthritis and ankylosing spondylitis.

### Claim 7 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, and dermatomyositis.

### Claim 8 (depends on 2)

The method of claim 2, wherein the patient in need thereof is suffering from one or more disease selected from Guillian Barre syndrome and multiple sclerosis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient is not afflicted with renal disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the patient is on hemodialysis or peritoneal dialysis.

### Claim 11 (depends on 1)

The method of claim 1, wherein the body fluid is blood.

### Claim 12 (depends on 1)

The method of claim 1, wherein the body fluid is plasma.

### Claim 13 (depends on 1)

The method of claim 1, wherein the body fluid is ultrafiltrate of plasma.

### Claim 14 (depends on 1)

The method of claim 1, wherein the body fluid is contacted with the renal tubule cells ex vivo.

### Claim 15 (depends on 1)

The method of claim 1, wherein the body fluid is contacted with the renal tubule cells inside the body of the patient.

### Claim 16 (depends on 1)

The method of claim 1, wherein the body fluid is contacted with the renal tubule cells in a renal tubule assist device.

### Claim 17 (depends on 16)

The method of claim 16, wherein the renal tubule assist device is ex vivo.

### Claim 18 (depends on 16)

The method of claim 16, wherein the renal tubule assist device is implanted in the patient.

### Claim 19 (depends on 1)

The method of claim 1, wherein the renal tubule cells are in a cell cartridge implanted in a blood vessel of the patient.

### Claim 20 (depends on 1)

The method of claim 1, wherein the level of at least one inflammatory cytokine is increased.

### Claim 21 (depends on 20)

The method of claim 20, wherein the inflammatory cytokine is a proinflammatory cytokine.

### Claim 22 (depends on 21)

The method of claim 21, wherein the proinflammatory cytokine is selected from the group consisting of TNF-α, IL-1, IL-1β, IL-6, IL-8, lipopolysaccharide-biding protein, MCP-1, CD-14, GM-CSF, G-CSF and a chemokine.

### Claim 23 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is TNF-α.

### Claim 24 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is IL-1.

### Claim 25 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is IL-1β.

### Claim 26 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is IL-6.

### Claim 27 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is IL-8.

### Claim 28 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is lipopolysaccharide-biding protein.

### Claim 29 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is MCP-1.

### Claim 30 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is CD-14.

### Claim 31 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is GM-CSF.

### Claim 32 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is G-CSF.

### Claim 33 (depends on 22)

The method of claim 22, wherein the proinflammatory cytokine is a chemokine.

### Claim 34 (depends on 20)

The method of claim 20, wherein the inflammatory cytokine is an anti-inflammatory cytokine.

### Claim 35 (depends on 34)

The method of claim 34, wherein the anti-inflammatory cytokine is selected from the group consisting of TNF-RI, TNF-RII, IL-1ra, IL-4, IL-10, IL-12, IL-13, TGF-β.

### Claim 36 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is TNF-RI.

### Claim 37 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is TNF-RII.

### Claim 38 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is IL-1ra.

### Claim 39 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is IL-4.

### Claim 40 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is IL-10.

### Claim 41 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is IL-12.

### Claim 42 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is IL-13.

### Claim 43 (depends on 35)

The method of claim 35, wherein the anti-inflammatory cytokine is TGF-β.

### Claim 44 (depends on 1)

The method of claim 1, wherein the level of at least one inflammatory cytokine is decreased.

### Claim 45 (depends on 44)

The method of claim 44, wherein the inflammatory cytokine is a proinflammatory cytokine.

### Claim 46 (depends on 45)

The method of claim 45, wherein the proinflammatory cytokine is selected from the group consisting of TNF-α, IL-1, IL-1β, IL-6, IL-8, lipopolysaccharide-biding protein, MCP-1, CD-14, GM-CSF, G-CSF and a chemokine.

### Claim 47 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is TNF-α.

### Claim 48 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is IL-1.

### Claim 49 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is IL-1β.

### Claim 50 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is IL-6.

### Claim 51 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is IL-8.

### Claim 52 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is lipopolysaccharide-biding protein.

### Claim 53 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is MCP-1.

### Claim 54 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is CD-14.

### Claim 55 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is GM-CSF.

### Claim 56 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is G-CSF.

### Claim 57 (depends on 46)

The method of claim 46, wherein the proinflammatory cytokine is a chemokine.

### Claim 58 (depends on 44)

The method of claim 44, wherein the inflammatory cytokine is an anti-inflammatory cytokine.

### Claim 59 (depends on 58)

The method of claim 58, wherein the anti-inflammatory cytokine is selected from the group consisting of TNF-RI, TNF-RII, IL-1ra, IL-4, IL-10, IL-12, IL-13, TGF-β.

### Claim 60 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is TNF-RI.

### Claim 61 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is TNF-RII.

### Claim 62 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is IL-1ra.

### Claim 63 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is IL-4.

### Claim 64 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is IL-10.

### Claim 65 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is IL-12.

### Claim 66 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is IL-13.

### Claim 67 (depends on 59)

The method of claim 59, wherein the anti-inflammatory cytokine is TGF-β.

### Claim 68

A method of modulating the levels of at least one inflammatory cytokine in a patient in need thereof, comprising:
removing a portion of body fluid from the patient,
contacting the removed body fluid with renal tubule cells, and
returning at least a portion of the body fluid which has been contacted with the renal tubule cells to the patient.

### Claim 69 (depends on 68)

The method of claim 68, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting of end-stage renal disease, chronic renal insufficiency, acute renal failure, sepsis, malnutrition, chronic congestive heart failure, inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, dermatomyositis, diabetes mellitus Type I, thyroiditis, psoriasis, Guillian Barre syndrome, multiple sclerosis, and atherosclerosis, or other autoimmune disorders.

### Claim 70 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting of end-stage renal disease, chronic renal insufficiency, acute renal failure, and sepsis.

### Claim 71 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from the group consisting malnutrition, chronic congestive heart failure, inflammatory bowel disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, dermatomyositis, diabetes mellitus Type I, thyroiditis, psoriasis, Guillian Barre syndrome, multiple sclerosis, and atherosclerosis, or other autoimmune disorders.

### Claim 72 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from inflammatory bowel disease, Crohn's disease, and ulcerative colitis.

### Claim 73 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from rheumatoid arthritis and ankylosing spondylitis.

### Claim 74 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from systemic vasculitis, lupus, Wegener's granulomatosis, polyarteritis nodosa, and dermatomyositis.

### Claim 75 (depends on 69)

The method of claim 69, wherein the patient in need thereof is suffering from one or more disease selected from Guillian Barre syndrome and multiple sclerosis.

### Claim 76 (depends on 68)

The method of claim 68, wherein the patient is not afflicted with renal disease.

### Claim 77 (depends on 68)

The method of claim 68, wherein the patient is on hemodialysis or peritoneal dialysis.

### Claim 78 (depends on 68)

The method of claim 68, wherein the body fluid is blood.

### Claim 79 (depends on 68)

The method of claim 68, wherein the body fluid is plasma.

### Claim 80 (depends on 68)

The method of claim 68, wherein the body fluid is ultrafiltrate of plasma.

### Claim 81 (depends on 68)

The method of claim 68, wherein the body fluid is contacted with the renal tubule cells ex vivo.

### Claim 82 (depends on 68)

The method of claim 68, wherein the body fluid is contacted with the renal tubule cells inside the body of the patient.

### Claim 83 (depends on 68)

The method of claim 68, wherein the body fluid is contacted with the renal tubule cells in a renal tubule assist device.

### Claim 84 (depends on 83)

The method of claim 83, wherein the renal tubule assist device is ex vivo.

### Claim 85 (depends on 83)

The method of claim 83, wherein the renal tubule assist device is implanted in the patient.

### Claim 86 (depends on 85)

The method of claim 85, wherein the renal tubule cells are in a cell cartridge implanted in a blood vessel of the patient.

### Claim 87 (depends on 68)

The method of claim 68, wherein the level of at least one inflammatory cytokine is increased.

### Claim 88 (depends on 87)

The method of claim 87, wherein the inflammatory cytokine is a proinflammatory cytokine.

### Claim 89 (depends on 88)

The method of claim 88, wherein the proinflammatory cytokine is selected from the group consisting of TNF-α, IL-1, IL-1β, IL-6, IL-8, lipopolysaccharide-biding protein, MCP-1, CD-14, GM-CSF, G-CSF and a chemokine.

### Claim 90 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is TNF-α.

### Claim 91 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is IL-1.

### Claim 92 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is IL-1β.

### Claim 93 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is IL-6.

### Claim 94 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is IL-8.

### Claim 95 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is lipopolysaccharide-biding protein.

### Claim 96 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is MCP-1.

### Claim 97 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is CD-14.

### Claim 98 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is GM-CSF.

### Claim 99 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is G-CSF.

### Claim 100 (depends on 89)

The method of claim 89, wherein the proinflammatory cytokine is a chemokine.

### Claim 101 (depends on 87)

The method of claim 87, wherein the inflammatory cytokine is an anti-inflammatory cytokine.

### Claim 102 (depends on 101)

The method of claim 101, wherein the anti-inflammatory cytokine is selected from the group consisting of TNF-RI, TNF-RII, IL-1ra, IL-4, IL-10, IL-12, IL-13, TGF-β.

### Claim 103 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is TNF-RI.

### Claim 104 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is TNF-RII.

### Claim 105 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is IL-1ra.

### Claim 106 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is IL-4.

### Claim 107 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is IL-10.

### Claim 108 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is IL-12.

### Claim 109 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is IL-13.

### Claim 110 (depends on 102)

The method of claim 102, wherein the anti-inflammatory cytokine is TGF-β.

### Claim 111 (depends on 68)

The method of claim 68, wherein the level of at least one inflammatory cytokine is decreased.

### Claim 112 (depends on 111)

The method of claim 111, wherein the inflammatory cytokine is a proinflammatory cytokine.

### Claim 113 (depends on 112)

The method of claim 112, wherein the proinflammatory cytokine is selected from the group consisting of TNF-α, IL-1, IL-1β, IL-6, IL-8, lipopolysaccharide-biding protein, MCP-1, CD-14, GM-CSF, G-CSF and a chemokine.

### Claim 114 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is TNF-α.

### Claim 115 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is IL-1.

### Claim 116 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is IL-1β.

### Claim 117 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is IL-6.

### Claim 118 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is IL-8.

### Claim 119 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is lipopolysaccharide-biding protein.

### Claim 120 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is MCP-1.

### Claim 121 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is CD-14.

### Claim 122 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is GM-CSF.

### Claim 123 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is G-CSF.

### Claim 124 (depends on 113)

The method of claim 113, wherein the proinflammatory cytokine is a chemokine.

### Claim 125 (depends on 111)

The method of claim 111, wherein the inflammatory cytokine is an anti-inflammatory cytokine.

### Claim 126 (depends on 125)

The method of claim 125, wherein the anti-inflammatory cytokine is selected from the group consisting of TNF-RI, TNF-RII, IL-1ra, IL-4, IL-10, IL-12, IL-13, TGF-β.

### Claim 127 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is TNF-RI.

### Claim 128 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is TNF-RII.

### Claim 129 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is IL-1ra.

### Claim 130 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is IL-4.

### Claim 131 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is IL-10.

### Claim 132 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is IL-12.

### Claim 133 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is IL-13.

### Claim 134 (depends on 126)

The method of claim 126, wherein the anti-inflammatory cytokine is TGF-β.
